Cargando…

Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals

In the absence of effective vaccines and with limited therapeutic options, convalescent plasma is being collected across the globe for potential transfusion to coronavirus disease 2019 (COVID-19) patients. The therapy has been deemed safe, and several clinical trials assessing its efficacy are ongoi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beaudoin-Bussières, Guillaume, Laumaea, Annemarie, Anand, Sai Priya, Prévost, Jérémie, Gasser, Romain, Goyette, Guillaume, Medjahed, Halima, Perreault, Josée, Tremblay, Tony, Lewin, Antoine, Gokool, Laurie, Morrisseau, Chantal, Bégin, Philippe, Tremblay, Cécile, Martel-Laferrière, Valérie, Kaufmann, Daniel E., Richard, Jonathan, Bazin, Renée, Finzi, Andrés
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2020
Materias:	Observation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569150/ https://www.ncbi.nlm.nih.gov/pubmed/33067385 http://dx.doi.org/10.1128/mBio.02590-20

Ejemplares similares

Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset
por: Anand, Sai Priya, et al.
Publicado: (2021)

Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset
por: Perreault, Josée, et al.
Publicado: (2020)

Humoral Responses Elicited after a Fifth Dose of SARS-CoV-2 mRNA Bivalent Vaccine
por: Tauzin, Alexandra, et al.
Publicado: (2023)

Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2
por: Gasser, Romain, et al.
Publicado: (2021)

Humoral Responses against BQ.1.1 Elicited after Breakthrough Infection and SARS-CoV-2 mRNA Vaccination
por: Tauzin, Alexandra, et al.
Publicado: (2023)

SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses
por: Chatterjee, Debashree, et al.
Publicado: (2022)

Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses
por: Tauzin, Alexandra, et al.
Publicado: (2022)

Antibody Binding to SARS-CoV-2 S Glycoprotein Correlates with but Does Not Predict Neutralization
por: Ding, Shilei, et al.
Publicado: (2020)

Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen
por: Nayrac, Manon, et al.
Publicado: (2021)

Spike recognition and neutralization of SARS-CoV-2 Omicron subvariants elicited after the third dose of mRNA vaccine
por: Tauzin, Alexandra, et al.
Publicado: (2023)

A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses
por: Tauzin, Alexandra, et al.
Publicado: (2022)

Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen
por: Nayrac, Manon, et al.
Publicado: (2022)

A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses
por: Tauzin, Alexandra, et al.
Publicado: (2021)

Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike
por: Prévost, Jérémie, et al.
Publicado: (2020)

Humoral immune responses against SARS-CoV-2 Spike variants after mRNA vaccination in solid organ transplant recipients
por: Tauzin, Alexandra, et al.
Publicado: (2022)

RESPONSE OF LYMPHOPENIC PLATELETPHERESIS DONORS TO COVID-19 VACCINATION
por: Bazin, Renee, et al.
Publicado: (2023)

A Recent SARS-CoV-2 Infection Enhances Antibody-Dependent Cellular Cytotoxicity against Several Omicron Subvariants following a Fourth mRNA Vaccine Dose
por: Beaudoin-Bussières, Guillaume, et al.
Publicado: (2023)

A new flow cytometry assay to measure antibody-dependent cellular cytotoxicity against SARS-CoV-2 Spike-expressing cells
por: Beaudoin-Bussières, Guillaume, et al.
Publicado: (2021)

The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice
por: Ullah, Irfan, et al.
Publicado: (2022)

SARS-CoV-2 Spike Expression at the Surface of Infected Primary Human Airway Epithelial Cells
por: Ding, Shilei, et al.
Publicado: (2021)

SARS-CoV-2 seroprevalence among blood donors in Québec, and analysis of symptoms associated with seropositivity: a nested case-control study
por: Lewin, Antoine, et al.
Publicado: (2021)

Seroprevalence of SARS-CoV-2 antibodies among blood donors in Québec: an update from a serial cross-sectional study
por: Lewin, Antoine, et al.
Publicado: (2022)

Temsavir Treatment of HIV-1-Infected Cells Decreases Envelope Glycoprotein Recognition by Broadly Neutralizing Antibodies
por: Boutin, Marianne, et al.
Publicado: (2022)

Covid-19 vaccine immunogenicity in people living with HIV-1
por: Nault, Lauriane, et al.
Publicado: (2022)

Small CD4 mimetics sensitize HIV-1-infected macrophages to antibody-dependent cellular cytotoxicity
por: Laumaea, Annemarie, et al.
Publicado: (2023)

Temperature Influences the Interaction between SARS-CoV-2 Spike from Omicron Subvariants and Human ACE2
por: Gong, Shang Yu, et al.
Publicado: (2022)

Evolution of Anti-RBD IgG Avidity following SARS-CoV-2 Infection
por: Tauzin, Alexandra, et al.
Publicado: (2022)

An extended SARS-CoV-2 mRNA vaccine prime-boost interval enhances B cell immunity with limited impact on T cells
por: Nicolas, Alexandre, et al.
Publicado: (2022)

Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes
por: Chatterjee, Debashree, et al.
Publicado: (2022)

SARS-CoV-2 Accessory Protein ORF8 Decreases Antibody-Dependent Cellular Cytotoxicity
por: Beaudoin-Bussières, Guillaume, et al.
Publicado: (2022)

Interaction of Human ACE2 to Membrane-Bound SARS-CoV-1 and SARS-CoV-2 S Glycoproteins
por: Anand, Sai Priya, et al.
Publicado: (2020)

Contribution of single mutations to selected SARS-CoV-2 emerging variants spike antigenicity
por: Gong, Shang Yu, et al.
Publicado: (2021)

Impact of HIV-1 Vpu-mediated downregulation of CD48 on NK-cell-mediated antibody-dependent cellular cytotoxicity
por: Marchitto, Lorie, et al.
Publicado: (2023)

Blood Endothelial-Cell Extracellular Vesicles as Potential Biomarkers for the Selection of Plasma in COVID-19 Convalescent Plasma Therapy
por: Amri, Nada, et al.
Publicado: (2022)

A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4(+) T cell profile
por: Sannier, Gérémy, et al.
Publicado: (2023)

Use of Early Donated COVID-19 Convalescent Plasma Is Optimal to Preserve the Integrity of Lymphatic Endothelial Cells
por: Amri, Nada, et al.
Publicado: (2022)

Humoral Responses Elicited by SARS-CoV-2 mRNA Vaccine in People Living with HIV
por: Marchitto, Lorie, et al.
Publicado: (2023)

Elicitation of Cluster A and Co-Receptor Binding Site Antibodies Are Required to Eliminate HIV-1 Infected Cells
por: Beaudoin-Bussières, Guillaume, et al.
Publicado: (2020)

Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality
por: Brunet-Ratnasingham, Elsa, et al.
Publicado: (2021)

Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy
por: Ullah, Irfan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qq6ulsl8u68olse0d9htu3ffk1